Clinical Data From Full Phase 1 Cohort Of Investigational Sotorasib Published In New England Journal Of Medicine
The Pharma Data
SEPTEMBER 20, 2020
“CodeBreaK 100 is the largest Phase 1/2, and first-in-human, clinical study for a KRAS G12C inhibitor,” said David M. executive vice president of Research and Development at Amgen. executive vice president of Research and Development at?Amgen, Reese , M.D., the ESMO Virtual Congress 2020. Sunday, Sept.
52 
Let's personalize your content